Five Prime Therapeutics Inc FPRX shares were unmoved late Friday after a hedge fund disclosed a 5 percent passive stake.
Point72 Asset Management LP revealed its acquisition of 1.27 million shares in a 13G filing.
Five Prime, a drug development company, closed at $24.97, up 0.24 percent. Its shares have more than doubled in value since November.
Earlier this month Adage Capital Partners, a Boston hedge fund, disclosed a 6.09 percent passive stake in Five Prime, which completed a public offering of about 3.8 million shares January 12.
Five Prime is developing drugs for cancer and inflammatory diseases. Last month the company launched a Phase 1 trial of its tumor-fighting drug FPA144 for gastric cancer.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.